View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 4, 2016

Teva completes $500 million acquisition of Allergan’s Anda

Israeli-based Teva Pharmaceutical Industries has completed the acquisition of Allergan’s generic pharmaceuticals distributor Anda, as part of a previously announced deal worth $500 million.

Israeli-based Teva Pharmaceutical Industries has completed the acquisition of Allergan ’s generic pharmaceuticals distributor Anda , as part of a previously announced deal worth $500 million.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Teva and Anda  reached an agreement to this effect in August this year.

As part of the deal, Teva acquired Anda 's distribution centres in Olive Weston, Florida; Branch, Mississippi; and Groveport, Ohio, with a total of more than 650 employees.

Teva Pharmaceutical Industries global generic medicines president and CEO Siggi Olafsson said: “We are pleased that Anda , one of the leading distributors of generic medicines in the US, is now part of Teva.

"This acquisition enables us and our customers to provide more patients throughout the country with access to generic medicines."

"This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for our business and for our extensive supply chain network in particular.

“This acquisition enables us and our customers to provide more patients throughout the country with access to generic medicines."

Anda is involved in the distribution of generic, brand, specialist and over-the-counter pharmaceutical products from more than 300 manufacturers to retail independent and chain pharmacies, mail order pharmacies, hospitals, nursing homes, clinics and physician offices across the US.

Anda president and CEO Charles D. Phillips said: “We are excited to become part of Teva’s distribution network to support our customers and patients across the country.

“By joining forces with Teva, Anda ’s product offerings will significantly increase and we will be able to reach more patients in the United States.”

Earlier in August, Teva also acquired Allergan ’s generics business Actavis Generics for $33.4 billion in cash.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology